Background: Pityriasis rosea (PR) is a self-limiting exanthematous disease associated with human herpesvirus (HHV)-6 and/or HHV-7 reactivation. In pregnant women, PR may be associated with pregnancy complications. Objective: To determine relevant risk factors in the development of negative pregnancy outcome in PR. Methods: Between 2005 and 2017 at the Department of Dermatology, University of Genoa, we recruited 76 women who developed PR during pregnancy. In 60 patients without known risk factors for intrauterine fetal death (30 with pregnancy complications and 30 without) we analyzed the pregnancy week of PR onset, presence of enanthem and of constitutional symptoms, PR body surface area involvement, age, and in 50 patients (20 with pregnancy complications and 30 without), the viral load of HHV-6 and HHV-7 (copies/mL). Results: In logistic regression analysis, early onset of PR (p = 0.0017) and enanthem (p = 0.0392) proved to be significantly associated with pregnancy complications. HHV-6 viral load (copies/mL) (p < 0.0001), constitutional symptoms (p < 0.001), and PR body surface area involvement (p < 0.004) were also significantly associated with pregnancy complications. Conclusion: The onset of PR before week 15 and enanthem may be considered major risk factors that should alarm the dermatologist. Constitutional symptoms and involvement of > 50% of the body area may be considered minor risk factors.

Keywords:
Pityriasis rosea, Pregnancy, Human herpesvirus 6, Human herpesvirus 7
1.
Drago F, Ciccarese G, Rebora A, Broccolo F, Parodi A: Pityriasis rosea: a comprehensive classification. Dermatology 2016; 232: 431–437.
2.
Drago F, Broccolo F, Ciccarese G, Rebora A, Parodi A: Persistent pityriasis rosea: an unusual form of pityriasis rosea with persistent active HHV-6 and HHV-7 infection. Dermatology 2015; 230: 23–26.
3.
Drago F, Ciccarese G, Gasparini G, Cogorno L, Javor S, Toniolo A, Broccolo F: Contemporary infectious exanthems: an update. Future Microbiol 2017; 12: 171–193.
4.
Corson EF, Luscombe HA: Coincidence of pityriasis rosea with pregnancy. AMA Arch Derm Syphilol 1950; 62: 562–564.
5.
Drago F, Broccolo F, Zaccaria E, Malnati M, Cocuzza C, Lusso P, Rebora A: Pregnancy outcome in patients with pityriasis rosea. J Am Acad Dermatol 2008; 58:S78–S83.
6.
Drago F, Broccolo F, Javor S, Drago F, Rebora A, Parodi A: Evidence of human herpesvirus-6 and -7 reactivation in miscarrying women with pityriasis rosea. J Am Acad Dermatol 2014; 71: 198–199.
7.
Broccolo F, Drago F, Careddu AM, Foglieni C, Turbino L, Cocuzza CE, Gelmetti C, Lusso P, Rebora AE, Malnati MS: Additional evidence that pityriasis rosea is associated with reactivation of human herpesvirus-6 and -7. J Invest Dermatol 2005; 124: 1234–1240.
8.
Bland M: An Introduction to Medical Statistics, ed 4. Oxford, Oxford University Press, 2015.
9.
Flamand L, Komaroff AL, Arbuckle JH, Medveczky PG, Ablashi DV: Review, part 1: Human herpesvirus-6-basic biology, diagnostic testing, and antiviral efficacy. J Med Virol 2010; 82: 1560–1568.
10.
Caserta MT, Hall CB, Schnabel K, Lofthus G, McDermott MP: Human herpesvirus (HHV)-6 and HHV-7 infections in pregnant women. J Infect Dis 2007; 196: 1296–1303.
11.
Ashshi AM, Cooper RJ, Klapper PE, Al-Jiffri O, Moore L: Detection of human herpes virus 6 DNA in fetal hydrops. Lancet 2000; 355: 1519–1520.
12.
Al-Buhtori M1, Moore L, Benbow EW, Cooper RJ: Viral detection in hydrops fetalis, spontaneous abortion, and unexplained fetal death in utero. J Med Virol 2011; 83: 679–684.
13.
Gervasi MT, Romero R, Bracalente G, Chaiworapongsa T, Erez O, Dong Z, Hassan SS, Yeo L, Yoon BH, Mor G, Barzon L, Franchin E, Militello V, Palù G: Viral invasion of the amniotic cavity (VIAC) in the midtrimester of pregnancy. J Matern Fetal Neonatal Med 2012; 25: 2002–2013.
14.
Drago F, Ciccarese G, Rebora A, Parodi A: Pityriasis rosea and pityriasis rosea-like eruption: can they be distinguished? J Dermatol 2014; 41: 864–865.
15.
Drago F, Broccolo F, Agnoletti A, Drago F, Rebora A, Parodi A: Pityriasis rosea and pityriasis rosea-like eruptions. J Am Acad Dermatol 2014; 70: 196.
16.
Ciccarese G, Broccolo F, Rebora A, Parodi A, Drago F: Oropharyngeal lesions in pityriasis rosea. J Am Acad Dermatol 2017; 77: 833–837.
17.
Drago F, Ciccarese G, Rebora A, Parodi A: Relapsing pityriasis rosea. Dermatology 2014; 229: 316–318.
18.
Drago F, Ciccarese G, Broccolo F, Ghio M, Contini P, Thanasi H, Parodi A: The role of cytokines, chemokines, and growth factors in the pathogenesis of pityriasis rosea. Mediators Inflamm 2015; 2015: 438963.
19.
Wagstaff AJ, Faulds D, Goa KL: Aciclovir. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic efficacy. Drugs 1994; 47: 153–205.
20.
Fölster-Holst R, Zawar VP, Chuh A: Paraviral exanthems. Expert Rev Anti Infect Ther 2016; 14: 601–611.
21.
Chang YH, Tseng JY, Chen CY, Sung PL, Yeh CC, Yang MJ: Acyclovir-induced nephrotoxicity in a pregnant woman with chickenpox. Taiwan J Obstet Gynecol 2016; 55: 618–619.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.